Journal of Cardiovascular Pharmacology最新文献

{"title":"Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin.","authors":"Juan Antonio Requena-Ibáñez, Mohammad Urooj Zafar, Marcos Ferrandez-Escarabajal, Gines Escolar, Carlos Santos-Gallego, David Lam, Juan José Badimon","doi":"10.1097/FJC.0000000000001747","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001747","url":null,"abstract":"<p><p>While selective SGLT2 inhibitors improve heart failure (HF) outcomes, they do not consistently reduce atherothrombotic events (myocardial infarctions and strokes). Clinical trials with sotagliflozin, the first dual SGLT1/2 inhibitor, have shown significant reductions in both HF outcomes and atherothrombotic events; an effect not seen with highly-selective SGLT2 inhibitors like empagliflozin. This effect may be related to SGLT1 inhibition, as SGLT1 is widely expressed in the myocardium, platelets, and endothelial cells, suggesting a potential antithrombotic mechanism. The SOTA-THROMBOSIS trial is a randomized, cross-over study in healthy volunteers (n=16) comparing the antithrombotic effects of dual SGLT1/2 inhibition with sotagliflozin and selective SGLT2 inhibition with empagliflozin. All participants will receive each treatment for 4-weeks, separated by a one-month washout. Blood thrombogenicity under high and low shear rate conditions will be assessed using the Badimon perfusion chamber. Additional assessments include platelet aggregation (Multiplate Analyzer) and clot formation kinetics using thromboelastometry (RoTEM). Measurements will be performed at baseline (pre-treatment) and at the end of each treatment period. The cross-over design - where each participant receives both study treatments and serves as his/her own control - significantly reduces both, intra-subject and intra-group variability. We hypothesize that both treatments will reduce blood thrombogenicity compared to baseline, with sotagliflozin offering a more marked antithrombotic effect than empagliflozin. This trial will provide novel mechanistic insights into the antithrombotic activity of SGLT1/2 inhibition. If confirmed, these findings may explain the additional cardiovascular protection observed with sotagliflozin and support its use in HF patients at high thrombotic risk.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapericardial Bleomycin for Malignant Pericardial Effusion: Revisiting a Targeted Pharmacologic Approach.","authors":"Danny L Rayes, Hira Latif, Syed Waqas Haider","doi":"10.1097/FJC.0000000000001746","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001746","url":null,"abstract":"<p><p>Malignant pericardial effusion, a complication of advanced malignancy, carries a poor prognosis and may be life-threatening in cases of cardiac tamponade. Treatment is challenging due to high recurrence rates. Management options include surgical pericardial window, extended catheter drainage, or intrapericardial sclerosing agents. While surgery remains the most definitive option for eligible patients, frailty and procedural morbidity are major limitations. Limited evidence suggests sclerosing agents provide comparable efficacy with improved tolerability. Bleomycin, a glycopeptide antibiotic with dual cytotoxic and sclerosing action, has emerged as a promising alternative, with recent evidence demonstrating efficacy similar to surgical drainage and superior tolerability compared to other agents. We highlight the advantages of bleomycin and its potential for broader adoption as an effective, well-tolerated, and palliative option in managing malignant pericardial effusion.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and Epigenetic Biomarkers in Hypertension: Impact on the Effectiveness of Individualized Therapy: A Systematic Review.","authors":"Anderson Matheus Pereira da Silva, Elaine da Silva Torres, Maria da Vitória Santos do Nascimento, Julia Oliveira Franco, Dillan Cunha Amaral, Anderson Silva Corin, Lívia Barbosa Cavalcanti, Maria Bernadete de Sousa Maia, Eryvelton de Souza Franco","doi":"10.1097/FJC.0000000000001743","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001743","url":null,"abstract":"<p><p>Arterial hypertension (AH) affects over 1.28 billion adults globally, remaining a leading cause of cardiovascular morbidity and mortality. Despite effective therapies, suboptimal blood pressure control persists, highlighting the need for precision approaches. Epigenetic biomarkers, particularly DNA methylation, have emerged as potential tools to enhance risk stratification and personalise antihypertensive therapy, yet their clinical relevance remains uncertain. To systematically synthesise evidence on genetic and epigenetic biomarkers associated with hypertension, focusing on DNA methylation signatures, regulatory pathways, and translational potential. We conducted a systematic review and meta-analysis following PRISMA guidelines, registered in PROSPERO (CRD420251059256). PubMed, MEDLINE, Embase, and ScienceDirect were searched up to March 2025. Eligible studies investigated genetic or epigenetic markers, such as DNA methylation, single nucleotide polymorphisms, or chromatin modifications in adult hypertension populations. Data on study design, populations, biomarkers, analytical methods, and outcomes were extracted. Risk of bias was assessed using RoB 2 and ROBINS-I tools. Twelve studies were included, encompassing cross-sectional and longitudinal designs. DNA methylation signatures at loci including AGTR1, PHGDH, SLC7A11, ACE, and WNT3A were recurrently associated with blood pressure regulation. Trans-ancestry genome-wide analyses identified methylation-enriched loci such as KCNK3, PDE3A, and PRDM6. However, no study demonstrated predictive value for clinical endpoints or robust replication across diverse populations. Methodological heterogeneity limited longitudinal data, and underrepresentation of low- and middle-income countries were key limitations. While epigenetic markers show promise for hypertension research, current evidence remains exploratory. Rigorous, longitudinal studies integrating clinical endpoints are essential for advancing toward clinical translation.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of regular exercise and resveratrol on hypertension-induced cellular stress response and senescence in renal and vascular tissues of rats.","authors":"Nur Banu Bal, Gökhan Sadi, Aykut Bostanci, Saba Kiremitci, Inga Adanir, Mecit Orhan Uludag, Emine Demirel-Yilmaz","doi":"10.1097/FJC.0000000000001744","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001744","url":null,"abstract":"<p><p>Hypertension remains the leading cause of morbidity and mortality worldwide and requires more understanding of its molecular basis. This study investigated cellular stress responses and senescence signaling in vascular and renal tissues of DOCA-salt hypertensive rats and the effect of resveratrol and exercise on these processes. Biochemical measurements in plasma and molecular (using Western Blot and qRT-PCR methods) and histopathologic (Hematoxylin-Eosin and Masson's Trichrome staining) examinations in the kidney and aorta were performed. The increase in kidney weight, kidney/body weight ratio, plasma BUN and creatinine levels of hypertensive animals was improved by exercise and resveratrol. Both interventions reduced GRP78/p-PERK-mediated ER stress and restored mitophagy via PINK1-SIRT3 in hypertensive renal and vascular tissues. Decreased vascular enos mRNA expression in hypertensive rats was enhanced by resveratrol treatment. The expression of NLRP3 inflammasome-related molecules and nf-ĸb in both tissues was increased in hypertensive animals. The positive effect of both treatments on inflammatory parameters was more pronounced in the kidney than in the aorta. The increased cellular senescence-related molecules p53 and il-6 were reversed by exercise and resveratrol in both tissues of hypertensive rats. Hypertension caused more obvious structural and inflammatory histopathologic changes in renal tissue than in vascular tissue. Regular exercise ameliorated these hypertension-induced renal alterations more than resveratrol. This study revealed that hypertension induces cellular stress responses including ER stress, impaired mitophagy, inflammation and consequently senescence, leading to structural alterations in a tissue-dependent manner. Regular exercise and resveratrol have different positive regulatory effects on these renal and vascular impairments caused by hypertension.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness.","authors":"Michele Marchetta, Michele Golino, John D Markley, Antonio Abbate","doi":"10.1097/FJC.0000000000001740","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001740","url":null,"abstract":"<p><p>The extensive use of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines has played a crucial role in controlling the Coronavirus disease 2019 (COVID-19) pandemic, underscoring the remarkable advantages and efficacy of novel vaccine technologies. However, rare but life-threatening cardiovascular complications such as myocarditis, pericarditis and thrombosis have emerged, predominantly affecting young males following their second vaccine dose. These adverse events highlight the importance of continued pharmacovigilance and transparent communication about potential risks. As the global epidemiological context has shifted, now characterized by widespread natural, vaccine-induced, or hybrid immunity, it is important to re-evaluate the risk-benefit ratio of repeated vaccine administration in low-risk individuals. Data regarding SARS-CoV-2 vaccines complications are still largely based on the early phases of the pandemic (2020-2021), when population-level immunity was minimal and severe COVID-19 outcomes more frequent. Today, such comparisons may no longer be appropriate. Updated real-world evidence is needed to better inform decision-making and ensure that public health strategies remain aligned with the contemporary risk landscape.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovation and Challenges in Preventive Cardiology: Highlights from ESC Preventive Cardiology 2025.","authors":"Svetlana Mosteoru, Giuseppe Biondi Zoccai, Luigi Spadafora","doi":"10.1097/FJC.0000000000001741","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001741","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPX4: A Key Regulator of Mitochondrial Function and Glycolysis in Pulmonary Artery Smooth Muscle Cells.","authors":"Hongli Zhang, Jihong Ren, Yan He, Kexin Zhao, Yuting He, Zhaoxia Sun, Yuanxin Zhu, Hongxia Bao, Shuang Wang","doi":"10.1097/FJC.0000000000001742","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001742","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disease characterized by elevated pulmonary arterial pressure and vascular remodeling. However, the underlying mechanisms remain unclear. This study reveals a novel mechanism by which oxidative stress reduced glutathione peroxidase 4 (GPX4) expression in both rat and human pulmonary arterial smooth muscle cells (PASMCs), establishing a reciprocal regulatory relationship between GPX4 and reactive oxygen species (ROS). GPX4 deficiency in PASMCs exacerbated inflammation, evidenced by increased IL-6 and TNF-α, and promoted extracellular matrix (ECM) remodeling, indicated by elevated fibronectin and collagen II. Moreover, GPX4 inhibition disrupted mitochondrial function by downregulating key mitochondrial regulators peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) and mitochondrial transcription factor A (TFAM). Simultaneously, it promoted glycolysis, leading to increased lactate production through the upregulation of lactate dehydrogenase A (LDHA) and hexokinase 2 (HK2). These effects were associated with the long non-coding RNA TUG1, which appeared to modulate GPX4 stability. Collectively, our findings identify GPX4 as a critical regulator of inflammation, ECM remodeling and metabolic homeostasis in PASMCs, providing new insights into the molecular mechanisms underlying PAH and identify potential therapeutic targets.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients with Atrial Fibrillation: A Cohort Study.","authors":"Mauro Trincado Ave, María Brión, Alejandro Blanco-Verea, Almudena Gil, Carlos Tilves, Ana Seoane Blanco, María Moure González, Federico García-Rodeja, Pablo de la Fuente, José Ramón González-Juanatey, Moisés Rodríguez Mañero","doi":"10.1097/FJC.0000000000001739","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001739","url":null,"abstract":"<p><p>A 25% flecainide dose reduction has been recommended for intermediate metabolisers (IMs); however, studies have yielded contradictory results, likely due to the lack of standardisation in CYP2D6 pharmacogenetic classifications. We aimed to address this gap. This cohort study included atrial fibrillation patients prescribed flecainide between 2017-2021. CYP2D6 was analysed, and patient phenotypes were classified using the current standard. For the primary outcome-6-month toxicity or recurrence-normal metabolisers (NMs) were compared with intermediate metabolisers (IMs). As a secondary objective, outcomes in poor metabolisers (PMs) and 12-month results were evaluated. A total of 104 patients were enrolled. Overall, 50% were NMs, 36.5% IMs, 6.7% PMs, and 6.7% others. There were no differences between IMs and NMs in the incidence of the primary outcome (29.0% vs 28.9%, p=0.99). No significant differences were observed in multivariate analysis (p=0.97) or 12-month follow-up (p=0.57). PMs had a lower event rate at 6 months (p=0.1), which became significant when the follow-up was extended to 1 year (univariate p=0.04; multivariate p=0.03). Using a standardised CYP2D6 classification, IMs and NMs showed similar rates of toxicity and recurrence when treated with 100 mg flecainide every 12 hours. Although the small sample size limits definitive conclusions, our findings challenge current recommendations to adjust dosing between NMs and IMs. In contrast, better outcomes were observed in PMs. This raises the question of whether, in an effort to minimise flecainide toxicity, dosing has inadvertently been standardised to subtherapeutic levels for all groups except PMs.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on artificial intelligence in medical publishing: a survey of medical journal editors.","authors":"Giuseppe Biondi-Zoccai, Attilio Lauretti, Stefan Agewall, Emmanuel Andres, Riccardo A Audisio, Deepak L Bhatt, Giuseppe Citerio, Jonathan A Drezner, Alexander Eggermont, Cetin Erol, Karen D Ersche, Giorgio Ferriero, Gerd Heusch, Ciro Indolfi, Paul A Insel, Carl J Lavie, Carlo La Vecchia, Nicola Maffulli, Fabrizio Montecucco, David J Moliterno, Stanley Nattel, Peter O'Kane, Elena Oliaro, Antonio Pelliccia, Michael Picard, Paolo Pozzilli, Fabiana Quaglia, Renata L Riha, Rupa Sarkar, Pietro Scicchitano, Jean-Louis Teboul, Hendrik Tevaearai Stahel, Loren E Wold, George W Booz","doi":"10.1097/FJC.0000000000001738","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001738","url":null,"abstract":"<p><p>Artificial intelligence (AI) has been increasingly integrated into medical publishing, hopefully improving efficiency and accuracy, but serious concerns persist regarding ethical implications, authorship attribution, and content reliability. We aimed at understanding the perspectives of editors of medical journals on AI. A structured online questionnaire was developed and distributed to Editors-in-Chief of medical journals worldwide. The survey comprised 27 concise questions exploring demographics, journal practices, and perspectives on AI in editorial workflows. Quantitative data were analyzed using descriptive statistics to summarize usage patterns, perceived benefits, risks, and future expectations. A total of 59 Editors-in-Chief completed the survey (response rate: 19%), with replies suggesting substantial variability in beliefs and attitudes towards AI for publication in medical journals. Artificial intelligence tools were already in use by 49% of journals, mainly for plagiarism detection (76%) and data verification (35%). Only 9% of responders reported that journals used AI for both scientific and linguistic review. Time savings (79%) and cost reduction (43%) were the most commonly cited benefits, and concerns included potential bias (71%) and lack of accountability (60%). Overall, 81% of responders anticipated a major role for AI in publishing within 10 years. Exploratory analyses suggested several potential associations between replies and respondent or journal features, requiring further validation in future surveys. In conclusion, the present survey on attitudes toward AI in publication in medical journals suggests that Editors-in-Chief are cautiously adopting AI in their editorial workflow, supporting its operational use while explicitly calling for clear guidance to address ethical and regulatory concerns.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phthalates and Cardiovascular Risk: A Call for Awareness in Clinical Practice.","authors":"Giuseppe Biondi-Zoccai, Vassilios S Vassiliou, Maria Camilla Palumbo, George W Booz","doi":"10.1097/FJC.0000000000001732","DOIUrl":"10.1097/FJC.0000000000001732","url":null,"abstract":"<p><strong>Abstract: </strong>Phthalates, widely used as plasticizers in industrial and medical products, are increasingly recognized as cardiovascular health disruptors. Their ubiquity poses a significant threat, particularly to patients with or at risk of cardiovascular disease. This review examines the multifactorial risks linked to phthalate exposure, including oxidative stress, epigenetic (re)programming, mitochondrial dysfunction, and endocrine disruption. Preclinical models-ranging from isolated cardiomyocytes to whole-animal systems demonstrate direct cardiotoxic effects, while epidemiological studies suggest a considerable global cardiovascular burden. Iatrogenic exposure through drug packaging, tubing, dialysis, and surgical equipment is especially concerning in frail patients, yet remains underrecognized in clinical guidelines. Vulnerable populations such as neonates, pregnant women, and patients undergoing cardiovascular procedures may face disproportionately high exposure levels. Despite the availability of safer alternatives, regulatory responses are inconsistent and clinical awareness is limited. Further longitudinal studies and biomarker-based surveillance are needed to quantify cumulative risk. Addressing this overlooked hazard is essential to protect patients from preventable harm and promote safer, precision cardiovascular care in the era of pervasive plastic use. We call for urgent reassessment of current practices, integration of environmental toxicology into medical training, and systematic adoption of phthalate-free materials.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}